Rohto Pharmaceutical's Earnings May Beat Guidance on Sales Momentum
Dow Jones
Yesterday
0510 GMT - Rohto Pharmaceutical's earnings for this fiscal year may beat its full-year guidance on strong sales momentum for its mainstay brands in Japan and overseas, Nomura analysts say in a research report. Its earnings are likely to stay robust as Nomura sees tailwinds for the pharmaceutical company's distinctive high-quality, affordable products from growth in the dermocosmetics market and consumers trading down in response to inflation. The brokerage lifts this fiscal year's operating-profit forecast for the Japanese company to 46.5 billion yen from Y45.7 billion. It raises the stock's target price to 3,650.0 yen from Y3,300.0 with an unchanged buy rating. Shares are 0.4% lower at Y2,791.5.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.